Very well run company, has come along way in a relatively short time, acquiring business to support gaps in their existing market and looking in earnest for other acquisitions to further bolster and future proof the business.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
